Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Insurance Press Releases.
Press releases published on April 25, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
GlobeNewswire
·
April 25, 2025
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. (“Adverum” or the “Company”) (NASDAQ: ADVM). Such investors are advised to contact Danielle Peyton at newaction@ …
Starton Therapeutics Presents Positive Data from Phase 1b Study Evaluating STAR-LLD for the Treatment of Relapsed/Refractory Multiple Myeloma at the American Association for Cancer Research (AACR) Annual Meeting 2025
GlobeNewswire
·
April 25, 2025
PARAMUS, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal technologies, announced today the presentation of positive data …
ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma
GlobeNewswire
·
April 25, 2025
- Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology’s investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R2) was well-tolerated and demonstrated promising anti-tumor activity - Combination …
Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
GlobeNewswire
·
April 25, 2025
Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission expected in 1H-2026 VANCOUVER, British Columbia, April …
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
GlobeNewswire
·
April 25, 2025
BDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events BDC-3042 showed biological activity, with clear dose-dependent increases in proinflammatory cytokines and chemokines BDC-3042 showed …
Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025
GlobeNewswire
·
April 25, 2025
Activity in preclinical models of ovarian, prostate, and non-small cell lung cancer supports potential utility of OP-3136, a KAT6 inhibitor, in indications beyond breast cancer Patient recruitment ongoing in Phase 1 trial of OP-3136 as a monotherapy and in …
IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170
GlobeNewswire
·
April 25, 2025
Preclinical data further support the potential of dual-antigen and TGF-β-directed vaccines to reshape the tumor microenvironment and drive anti-tumor immunity NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage …
SAG HOLDINGS LIMITED CHANGE ITS NAME TO INNEOVA HOLDINGS LIMITED
GlobeNewswire
·
April 25, 2025
Corporate Rebranding Marks New Era of Engineering Excellence and Sustainable Solutions SINGAPORE, April 25, 2025 (GLOBE NEWSWIRE) -- SAG Holdings Limited today announced that it has changed its name to INNEOVA Holdings Limited (“INNEOVA Holdings” or the “ …
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
GlobeNewswire
·
April 25, 2025
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw …
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Strategy Incorporated (f/k/a MicroStrategy Incorporated) - MSTR
GlobeNewswire
·
April 25, 2025
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Strategy Incorporated (f/k/a MicroStrategy Incorporated) (“Strategy” or the “Company”) (NASDAQ: MSTR). Such investors are advised to contact …
American Rebel CEO Andy Ross Harnesses Media Appearance on NBC-TV West Palm Beach Affiliate to Amplify Growth Strategy, Propel Brand Expansion and Launch American Rebel Light Beer in Florida
GlobeNewswire
·
April 25, 2025
From Song to Strategy: American Rebel's CEO Andy Ross Shares the Brand's Journey with Sunshine Spotlight Host Fiona Daghir Detailing the Journey of America’s Patriotic Brand to Becoming the Next Great American Success Story. West Palm Beach, FL, April 25, …
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines – ZBIO
GlobeNewswire
·
April 25, 2025
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. (“Zenas” or the “Company”) (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@ …
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of TechTarget, Inc. – TTGT
GlobeNewswire
·
April 25, 2025
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of TechTarget, Inc. (“TechTarget” or the “Company”) (NASDAQ: TTGT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or …
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agilysys, Inc. - AGYS
GlobeNewswire
·
April 25, 2025
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Agilysys, Inc. (“Agilysys” or the “Company”) (NASDAQ: AGYS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646 …
Transaction in Own Shares
GlobeNewswire
·
April 25, 2025
Transaction in Own Shares 25 April, 2025 • • • • • • • • • • • • • • • • Shell plc (the ‘Company’) announces that on 25 April 2025 it purchased the following number of Shares for cancellation. Aggregated information on Shares purchased according to trading …
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Treace Medical Concepts, Inc. - TMCI
GlobeNewswire
·
April 25, 2025
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NASDAQ: TMCI). Such investors are advised to contact Danielle Peyton at …
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – VTRS
GlobeNewswire
·
April 25, 2025
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Viatris Inc. (NASDAQ: VTRS) between August 8, 2024 and February 26, 2025, both dates inclusive (the “Class Period”), of …
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Viatris Inc. of Class Action Lawsuit and Upcoming Deadlines - VTRS
GlobeNewswire
·
April 25, 2025
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Viatris, Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw. …
Fundraising Effectiveness Project Data for Q4 2024 highlights the growing role of high-dollar donors in driving fundraising performance across the sector
GlobeNewswire
·
April 25, 2025
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Q4 2024 fundraising data from the Fundraising Effectiveness Project (FEP) released today shows an increase of 3.5% in dollars raised compared to 2023 levels. However, despite the increase in total dollars, it is …
Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)
GlobeNewswire
·
April 25, 2025
UK Medicines and Healthcare products Regulatory Agency (MHRA) authorisation based on FELIX clinical trial of obecabtagene autoleucel in adult patients with r/r B-ALL1 AUCATZYL® licensed from MHRA under ‘conditional marketing authorisation’, meaning that …